Brief: Lianbio Announces First Patient Treated In Phase 1 Trial Of Shp2 Inhibitor Bbp-398
03/08/2023 21:38
Aug 3 (Reuters) - LianBio LIAN.O :
* LIANBIO ANNOUNCES FIRST PATIENT TREATED IN PHASE 1 TRIAL
OF SHP2
INHIBITOR BBP-398 IN COMBINATION WITH OSIMERTINIB IN PATIENTS
WITH NON-SMALL CELL LUNG CANCER WITH EGFR MUTATIONS
Source text for Eikon: ID:nGNX9NgwP8
Further company coverage: LIAN.O
Recent news on LianBio
See all newsChina's Zeekr prices US IPO at top of range to raise $441 million (updated)
U.S. STOCKS ON THE MOVE-JetBlue Airways, LPL Financial, Nvidia
U.S. STOCKS ON THE MOVE-Bicycle Therapeutics, Molson Coors, LianBio
LianBio completes strategic review, cuts jobs; shares up
Brief: LianBio Announces Completion Of Strategic Review